



# Genetic analysis in a large cohort of patients with hereditary spastic paraplegia: diagnostic challenges

**Sara Morais<sup>1,2</sup>, Ana Filipa Brandão<sup>1,2</sup>, Ana Lopes<sup>1,2</sup>, Rita Bastos-Ferreira<sup>1,2</sup>, Susana Sousa<sup>1,2</sup>, Paulo Silva<sup>1,2</sup>, Fátima Lopes<sup>1,2</sup>, Alexandra Lopes<sup>1,2</sup>, Joana Damásio<sup>1,2,3</sup>, José Leal Loureiro<sup>4</sup>, Marina Magalhães<sup>3,5</sup>, Miguel Leão<sup>6</sup>, Cristina Costa<sup>7</sup>, Ricardo Maré<sup>8</sup>, Jorge Sequeiros<sup>1,2</sup>, João Freixo<sup>1,2</sup>, Jorge Oliveira<sup>1,2</sup>**

1- CGPP-IBMC – Centro de Genética Preditiva e Preventiva, Instituto de Biologia Molecular e Celular, Universidade do Porto, Portugal; 2- i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal; 3- Serviço de Neurologia, Hospital de Santo António, Centro Hospitalar Universitário do Porto, Portugal; 4- Serviço de Neurologia, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal; 5- Serviço de Neurologia, Hospital Padre Américo, Centro Hospitalar do Tâmega e Sousa, Portugal; 6- Serviço de Genética, Centro Hospitalar de São João/Faculdade de Medicina da Universidade do Porto, Portugal; 7- Serviço de Neurologia, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal; 8- Serviço de Neurologia, Hospital de Braga, Portugal

## Background

- **Hereditary Spastic Paraplegia (HSP):** group of rare neurodegenerative disorders
- Main symptoms:
  - Slowly progressive spasticity
  - Weakness of the lower limbs
  - May include additional neurologic and non-neurologic features
- Estimated prevalence in Europe: 3-10/100,000
- Pathologically characterized by axonal degeneration of the longest nerve fibers in the corticospinal tracts


## Genetic aetiology

> 70 identified *loci*

still



40 - 70% of the families without a molecular diagnosis



## Aim

Molecular diagnosis of 472 HSP patients (index cases)

## Strategy

Single-gene tests

Whole-exome sequencing  
based multigene panels

## Results

**118 patients**  
(with molecular diagnosis)

**90 patients**  
(with molecular diagnosis)


**7 patients**  
(with variants of unknown clinical  
significance (VUS))

**61 patients**  
(with variants of unknown clinical  
significance (VUS))

**11 patients**  
(with single heterozygous variants in  
AR-associated genes)

**50 patients**  
(with single heterozygous variants in  
AR-associated genes)

**Total patients  
(n=472)**




■ Molecular diagnosis; 
 ■ VUS; 
 ■ Single heterozygous variants; 
 ■ No variants.


## Results

Identification of 368 different variants in 87 genes

Type of variants:




■ Missense; ■ Nonsense;  
■ Splicing; ■ Frameshift;  
■ Large rearrangements; ■ 5'UTR or 3'UTR.



■ Novel; ■ Reported.

Disease-causing variants identified in 33 genes




■ SPAST (42.8%); ■ SPG11 (12%); ■ SPG7 (5.8%); ■ ZFYVE26 (5.3%); ■ ATL1 (4.3%);  
 ■ CYP7B1 (3.8%); ■ CAPN1 (2.9%); ■ KIF5A (2.9%); ■ SACS (2.9%); ■ ARG1 (1.4%);  
 ■ ATP13A2 (1.4%); ■ B4GALNT1 (1%); ■ BSCL2 (1%); ■ CYP27A1 (1%); ■ KCNA2 (1%);  
 ■ KIF1A (1%); ■ REEP1 (1%); ■ REEP2 (1%); ■ RNASEH2B (1%); ■ ABCD1 (0.5%);  
 ■ ALS2 (0.5%); ■ CYP2U1 (0.5%); ■ DDHD1 (0.5%); ■ FA2H (0.5%); ■ GALC (0.5%);  
 ■ GBA2 (0.5%); ■ GJC2 (0.5%); ■ NFU1 (0.5%); ■ NIPA1 (0.5%); ■ PLP1 (0.5%);  
 ■ SLC2A1 (0.5%); ■ SYNE1 (0.5%); ■ TUBB4A (0.5%).

## Results

## Interesting case reports

### Case #1


1 year-old male with pure spastic paraplegia. Normal brain MRI. Spastic hypertonia of the lower limbs.



homozygous variant in *ALS2*  
NM\_020919.3:c.[4261C>T];[c.4261C>T]  
// p.(Arg1421\*)

### Case #2


58 year-old male with spastic paraplegia.



homozygous variant in *GALC*  
NM\_000153.3:c.[927A>C];[927A>C]  
// p.(Leu309Phe)

### Case #3

9 year-old female with spastic paraplegia. Polyneuropathy.



homozygous variant in *SYNE1*  
NM\_182961.3(SYNE1):c.[21401del];  
[21401del] // p.(Ser7134Ilefs\*9)

Identification of variants in genes causing overlapping phenotypes in patients with an apparent pure spastic paraplegia phenotype

## Conclusions

This work:

1. Contributed to the molecular, clinical and genetic heterogeneity of HSPs.
2. Demonstrates the importance of **testing genes defective in other differential diagnosis**, with overlapping clinical features (such as *SACS*, *ARG1* and *KCNA2*) – strong implications in NGS panels design.
3. Depicted a **high number of patients with VUS and/or single heterozygous variants** in genes associated to diseases with an autosomal recessive inheritance - besides the importance of identifying a missing pathogenic allele, highlighted:
  - the difficulty of interpreting VUS;
  - the importance of functional studies to clarify their causative role and, ultimately, provide a definitive diagnosis of HSP;
  - the possibility of finding, among these variants/*locus*, further modes of genetic inheritance, even of oligogenic nature.
4. The number of patients without variants reported (n=135) might indicate that a large number of HSPs causing genes and probably **novel pathogenic mechanisms** leading to the disease are yet to be discovered.

## References

- Boutry et al. 2019. *Curr Neurol Neurosci Rep.* 19(4):18.
- Salinas et al. 2008. *Lancet Neurol.* 7(12):1127-38.
- Morais et al. 2017. *Eur J Hum Genet.* 25(11):1217-1228.
- Tesson et al. 2015. *Hum. Genet.* 134, 511–538.